SeekingAlpha  Feb 5  Comment 
Vascular Solutions, Inc. (VASC) Q4 2013 Earnings Conference Call February 4, 2014 04:30 p.m. ET Executives Phil Nalbone – Vice President, Corporate Development Howard Root – CEO James Hennen – SVP Finance & CFO ...
StreetInsider.com  Feb 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Tops+Q4+EPS+by+3c/9124580.html for the full story.
Benzinga  Nov 11  Comment 
ITGI announces today the initiation of its activity in the U.S. market. The company has signed a strategic cooperation agreement with U.S.-based Vascular Solutions, Inc. (NASDAQ: VASC), an international leader in the...
StreetInsider.com  Oct 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Tops+Q3+EPS+by+12c%3B+Issues+Strong+Guidance/8799721.html for the full story.
StreetInsider.com  Jul 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Reports+In-Line+Q2+EPS%3B+Reaffirms/8524630.html for the full story.
Benzinga  May 16  Comment 
Vascular Solutions (Nasdaq: VASC) announced today that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (NYSE: BSX). The complaint alleges that Boston...
StreetInsider.com  Apr 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Tops+Q1+EPS+by+1c/8272520.html for the full story.
MedPage Today  Mar 28  Comment 
WASHINGTON (MedPage Today) -- The FDA has issued class I recalls on two hemostasis valves manufactured by Vascular Solutions because of a risk of air embolism.
Benzinga  Mar 27  Comment 
In a report published Wednesday, Piper Jaffray analyst Thomas J. Gunderson initiated coverage on Vascular Solutions (NASDAQ: VASC) with an Overweight rating and $18.00 price target. In the report, Gunderson noted, “We are initiating coverage...
Benzinga  Mar 18  Comment 
In a report published Monday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $20.50 price target on Vascular Solutions (NASDAQ: VASC). In the report, Mills noted, “Vascular Solutions announced that it initiated a...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki